Skip to main content

MiReven Publishes Data on Role of microRNA in Cancer


Australian microRNA drug firm MiReven announced this week the publication of in vitro data validating the role of miR-7-5p in cancer.

The findings, which appeared in Biochemical and Biophysical Research Communications and were authored by a company co-founder, showed that the miRNA was reduced in metastatic melanoma-derived cell lines compared with primary melanoma cells.

Upon re-introduction of the miRNA and its ectopic expression, “migration and invasion of the melanoma cells was significantly inhibited in vitro,” the company said. The report also demonstrated that insulin receptor substrate-2 is a functional target of miR-7-5p, which then “decreases activity in the protein kinase B signaling pathway, a key regulator of many oncogenic processes including cell migration.”

MiReven is currently developing a miR-7 mimic as a treatment for cancer.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.